Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG

PolyPeptide Group / Key word(s): Transaction in Own Shares

10-Nov-2021 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Media Release

Ad hoc announcement pursuant to Art. 53 LR

Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG

Zug, 10 November 2021 - PolyPeptide Group AG ("PolyPeptide") has been informed that Draupnir Holding B.V. ("Draupnir"), which held 60.0% of PolyPeptide's share capital as of close of trading on SIX Swiss Exchange yesterday, placed a total of 1,500,000 existing ordinary shares in PolyPeptide (representing approx. 4.5% of PolyPeptide's share capital) through an accelerated bookbuilding offering to institutional investors overnight. Upon settlement of the placement, which is expected to occur on 12 November 2021 subject to customary closing conditions, Draupnir will hold approx. 55.5% of PolyPeptide's share capital. The free float in PolyPeptide shares, which according to SIX Swiss Exchange is presently 40.0%, will increase by approx. 4.5% to approx. 44.5%.

In the context of the placement, Draupnir has undertaken a lock-up commitment for a period of 130 days with respect to shares in PolyPeptide that will remain in its possession upon completion of the placement and PolyPeptide has been informed that Draupnir is committed to maintain a majority ownership in PolyPeptide for the foreseeable future.

Contact

PolyPeptide Group AG
Michael Stäheli
Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com
Tel. +41 41 723 20 34

About PolyPeptide

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 1,000 employees, its diversity brings breadth, depth of knowledge and experience to the Group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, visit polypeptide.com.

PolyPeptide Group AG, Dammstrasse 19, CH-6300 Zug

Disclaimer

This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.

This document contains forward-looking statements including, but not limited to, statements regarding the completion of the transaction described herein, and Draupnir's investment in PolyPeptide Group AG. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results, performance or events to differ materially from the statements made herein.